Tel: (92)  51 9270076 | Email:

Blood & Marrow October 2018 Vol 2.10

Read Online
Blood & Marrow October 2018 Vol 2.10

  • Tutorial – Antithrombotic Agents (Part-II)
  • Conference Coverage – ICBMT-2018
  • Journal Scan
  • B&M News – 3rd EBMT International Transplant Course
  • Nurse’s Nook – Oral Mucositis
  • B&M News – Nobel Prize in Medicine Goes to Cancer Immunotherapy Pioneers

After 40 years of little improvement since A the advent of cytarabine and daunorubicin, Things have started to change for patients with Acute Myeloid Leukemia (AML). Better understanding of disease, improved classification & risk stratification has paved way for development of many new drugs for AML. After chemotherapy and stem cell transplant, targeted therapies are now becoming important part of treatment in some patients with AML. Four new agents were approved for AML by the FDA in 2017 alone: Midostaurin, CPX-351, Gemtuzumab ozogamacin and Enasidenib. Many new classes of drugs including FLT3 inhibitors, IDH inhibitors. Histone deacetylase inhibitors, BCL-2 inhibitors, Polo-lie kinase inhibitors, monoclonal antibodies and immune checkpoint inhibitors have shown promise. Last but not least, is the CAR T-cell therapy, a new way to get immune system to fight leukemia. Winds of change are finally bringing new hope beyond “7+3″ for patients with AML.